Bellerophon Therapeutics Inc
NASDAQ:BLPH
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Bellerophon Therapeutics Inc
Additional Paid In Capital
Bellerophon Therapeutics Inc
Additional Paid In Capital Peer Comparison
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Bellerophon Therapeutics Inc
NASDAQ:BLPH
|
Additional Paid In Capital
$259.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
Becton Dickinson and Co
NYSE:BDX
|
Additional Paid In Capital
$19.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
25%
|
|
Boston Scientific Corp
NYSE:BSX
|
Additional Paid In Capital
$20.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
Stryker Corp
NYSE:SYK
|
Additional Paid In Capital
$2.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
Abbott Laboratories
NYSE:ABT
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Additional Paid In Capital
$8.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
See Also
What is Bellerophon Therapeutics Inc's Additional Paid In Capital?
Additional Paid In Capital
259.9m
USD
Based on the financial report for Sep 30, 2023, Bellerophon Therapeutics Inc's Additional Paid In Capital amounts to 259.9m USD.
What is Bellerophon Therapeutics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
8%
Over the last year, the Additional Paid In Capital growth was 2%. The average annual Additional Paid In Capital growth rates for Bellerophon Therapeutics Inc have been 1% over the past three years , 8% over the past five years .